Invivyd Doses First Patients in LIBERTY Phase 3 Trial for VYD2311 COVID Antibody
IVVD has more than doubled off its 52-week low of $0.483.
Summary
Invivyd announced the dosing of the first participants in its LIBERTY Phase 3 clinical trial for VYD2311, a COVID-19 antibody candidate. This trial, part of the broader REVOLUTION program, will evaluate VYD2311's safety and tolerability against mRNA COVID vaccines, and also co-administration. This follows the recent completion of enrollment for the DECLARATION Phase 3 trial for the same candidate, and prior announcements of significant program progress. Initiating a second Phase 3 trial for its lead candidate is a major milestone for the clinical-stage biotech, advancing its path towards potential regulatory approval. Topline data from LIBERTY is expected in Q3 2026, coinciding with anticipated data from the DECLARATION trial.
At the time of this announcement, IVVD was trading at $1.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $300.5M. The 52-week trading range was $0.48 to $3.07. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.